We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' p... Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. Show more
– Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session – – Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b...
– Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 – – Received $1.1 Billion in Payments from Royalty...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.465 | 0.810245687402 | 57.39 | 59.86 | 56.67 | 421482 | 58.95355856 | CS |
4 | 13.315 | 29.8944768747 | 44.54 | 62.58 | 43.25 | 723368 | 55.92126134 | CS |
12 | 13.655 | 30.8936651584 | 44.2 | 62.58 | 39.94 | 593229 | 49.32185153 | CS |
26 | 20.985 | 56.916192026 | 36.87 | 62.58 | 36.39 | 597692 | 47.26070548 | CS |
52 | 35.025 | 153.416557162 | 22.83 | 62.58 | 20.96 | 681062 | 36.81914147 | CS |
156 | 21.955 | 61.1559888579 | 35.9 | 62.58 | 16.75 | 605956 | 30.3227788 | CS |
260 | 19.405 | 50.4681404421 | 38.45 | 62.58 | 16.75 | 637246 | 37.32757417 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions